Eosinophilia News and Research

RSS

Eosinophils are a type of blood cells which helps to fight off certain infections and participates in the body’s immune reactions. Eosinophilia is a condition in which the peripheral blood contains an excessive number of eosinophils, more than 500/µL. It may be classified into mild (500-1500/µL); moderate (1500-5000/µL); and severe (over 5000/µL) eosinophilia.

Rapid test could determine the existence of a key driver of severe asthma

Based on decades of work to uncover the underlying mechanisms of asthma and other respiratory conditions, researchers at McMaster University and St. Joseph's Healthcare Hamilton have produced a simple, rapid test that can identify the presence of a key driver of severe asthma.

2 Aug 2023

Dietary inulin fiber can promote allergy-related type of inflammation in the gut and lungs

A type of dietary fiber called inulin, commonly used in health supplements and known to have certain anti-inflammatory properties, can also promote an allergy-related type of inflammation in the lung and gut, and other parts of the body, according to a preclinical study from researchers in the Friedman Center for Nutrition and Inflammation and Jill Roberts Institute for Inflammatory Bowel Disease at Weill Cornell Medicine and in the Boyce Thompson Institute on Cornell's Ithaca campus.

2 Nov 2022

How does obesity affect the immune system?

A new study summarizes new findings on the immunoregulatory effects of excessive fat stores or malnutrition through Th2 cells.

4 Jul 2022

A comparison of SARS-CoV-2 and influenza cytokine storms

In a recent study published in the Journal of Interferon & Cytokine Research, researchers compared the cytokine storms of pandemic influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

9 Jun 2022

Measuring airway inflammation when diagnosing and treating asthma patients

In this interview, Carol Stonham, the head of a Locality Based FeNO referral service, talks to NewsMed about measuring airway inflammation when diagnosing and treating asthma patients.

From Bedfont® Scientific Ltd 21 Dec 2021

A nematode infection can become severe and deadly with the use of corticosteroids

Healthcare workers in tropical and sub-tropical settings where strongyloidiasis is prevalent or caring for patients who have travelled to such areas, need to maintain a high level of awareness about the use of corticosteroids, including when this class of anti-inflammatories is given to patients suspected of infection with SARS-CoV-2.

19 Dec 2021

Phenome study reveals alternate associations with SARS-CoV-2 risk loci

Researchers from the Duke Molecular Physiology Institute have been investigating genetic associations with more severe disease and examining the associations that certain genetic features have with other diseases.

13 Dec 2021

Discovery of biological response platform could provide opportunity to alleviate allergic inflammation

New discoveries about a built-in rapid reaction system that triggers inflammatory responses when people are exposed to allergens, such as insects, mites, and fungi, also may hold the keys to helping more people manage their allergies in years to come.

17 Sep 2021

Study may lead to new therapies for patients suffering from Duchenne muscular dystrophy

A new study, led by the University of California, Irvine (UCI), reveals how chronic inflammation promotes muscle fibrosis, which could inform the development of new therapies for patients suffering from Duchenne muscular dystrophy (DMD), a fatal muscle disease.

15 Apr 2021

COVID-19 pandemic highlights the risk of using systemic corticosteroids

17 Dec 2020

FDA approves first drug for patients with hypereosinophilic syndrome in nearly 14 years

Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.

25 Sep 2020

Immunologists analyze types of immune response to predict an effective COVID-19 vaccine

Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition.

15 Sep 2020

Researchers identify gene that increases risk of antibiotic reaction

Researchers at Vanderbilt University Medical Center and colleagues have identified a gene that increases the risk for a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin.

11 Mar 2019

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

Phase 2 study of dexpramipexole in hypereosinophilic syndromes meets its co-primary endpoints

Knopp Biosciences LLC today announced the publication of a report in the journal Blood that a Phase 2 study of dexpramipexole in hypereosinophilic syndromes met its co-primary endpoints.

10 May 2018

Penicillin allergy testing: an interview with Dr. Eric Macy

Penicillin was one of the first antibiotics developed and has saved millions of lives. First used in the early 1940s, penicillin is still one of the most widely used and least toxic family of antibiotics.

17 Aug 2016

Over-expression of heme oxygenase-1 enzyme protects the heart from doxorubicin damage

Life-threatening heart damage is an adverse side effect of the cancer drug doxorubicin, damage that also limits the use of newer chemotherapeutic agents such as trastuzumab and imatinib. The ability to protect the heart from these side effects would benefit patients, including cancer survivors who are at risk of developing heart damage years later, and it also could allow safer use of these drugs at higher doses.

26 Feb 2016

Presence of blood eosinophilia during NEC predicts life-threatening complications for preemies

Premature infants have heightened risks of deadly diseases because their organs and immune systems are not fully developed. Necrotizing enterocolitis (NEC), a major gastrointestinal disease that causes the intestines to die, is a leading cause of death among these infants and is the most the common disease for babies born before 32 weeks.

1 Oct 2015

Atopix raises additional development capital to investigate OC459 for treatment of asthma

Atopix Therapeutics Limited, a UK biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma, today announced that it has raised additional development capital to advance its lead product OC459 for the treatment of asthma.

17 Jun 2015